Remdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological data available on the COVID-19 outbreak in France and data from two randomized control trials. Strategies involving treating with remdesivir only patients with low-flow oxygen and patients with low-flow and high-flow oxygen were examined. Treating all eligible low-flow oxygen patients during the entirety of the second wave would have decreased hospital-bed occupancy in conventional wards by 4% [2%; 7%] and intensive care unit (ICU)-bed occupancy by 9% [6%; 13%]. Extending remdesivir use to high-flow-oxygen patients would have amplified reductions in ICU-bed occupancy by up to 14% [18%; 11%]. A minimum remdesivir uptake of 20% was required to observe decreases in bed occupancy. Dexamethasone had effects of similar amplitude. Depending on the treatment strategy, using remdesivir would, in most cases, generate savings (up to 722€) or at least be cost neutral (an extra cost of 34€). Treating eligible patients could significantly limit the saturation of hospital capacities, particularly in ICUs. The generated savings would exceed the costs of medications.
【초록키워드】 Dexamethasone, Treatment, intensive care, hospital, Strategy, Remdesivir, drug, medications, COVID-19 outbreak, Impact, Patient, France, second wave, epidemiological data, resource, COVID-19 patients, Randomized control trials, Neutral, Hospital stay, High-flow oxygen, ICUs, amplitude, low-flow oxygen, Effect, limit, decrease, treating, observé, amplified, affected, examined, significantly, required, generate, reductions in, eligible, eligible patient, 【제목키워드】 Dexamethasone, hospital, resource, Care,